MoonLake stock jumps after FDA feedback clears path for sonelokimab filing without new HS trials
MoonLake Immunotherapeutics shares surged 27% to $14.34 in after-hours trading Thursday after the company said the FDA may allow approval of its hidradenitis suppurativa drug sonelokimab based on existing trial data. The company plans to file for approval in the second half of 2026 and will hold an investor day on Feb. 23.